Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best rebound stocks to buy right now. On March 2, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) outlined its growth strategy at the TD Cowen 46th Annual Health Care Conference, emphasizing significant revenue expansion and ongoing innovation in RNAi therapies.

The company expects revenue of around $4.4 billion to $4.7 billion by 2026, indicating strong growth and a 25% CAGR through 2030. It also aims for 30% operating margins, which might rise to the mid-40% levels after future product releases. A significant aim is to reinvest 30% of sales in R&D to accelerate pipeline advancement.

With more than 90% first-line patient access, AMVUTTRA continues to be a significant growth driver as Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) gets primed for competition from WAINUA. The company is also advancing its pipeline, which includes the TRITON research, alongside plans to broaden into 10 tissues by 2030.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a prominent biopharmaceutical company focused on RNA interference (RNAi) treatments, with a number of FDA-approved medications for rare genetic diseases.

While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.